Can India growth offset pressure in the US business?

Sun Pharmaceutical Industries Limited (

) is scheduled to announce its Q2 FY27 results today. Investors will be tracking domestic formulations, global innovative medicines and the impact of acquisition-related expenses on profitability Previous quarter snapshot Revenue from operations: ₹15,299.88 crore, up 10.5% year-on-year. Reported net profit: ₹2,894.79 crore, up 27%. Adjusted net profit: ₹3,089.40 crore, up 3.1%. EBITDA: ₹4,417.70 crore, up 2.7%. EBITDA margin: 28.9%, down from 31.1%. India formulations sales grew 16%, while US formulations sales declined 9.7%. Why Q2 matters The previous quarter showed healthy domestic growth, but EBITDA margins contracted and US sales remained under pressure. The market will want to see whether innovative medicines and India formulations can sustain growth while costs remain controlled. What to monitor India formulations growth. US business recovery and specialty portfolio performance. EBITDA margin and operating expenses. R&D spending and acquisition-related costs. Management commentary on the Organon acquisition. My analytical view Sun Pharma has a diversified business and strong domestic presence. However, the key earnings signal will be whether revenue growth translates into better operating profitability. Investors should look beyond reported net profit and examine adjusted earnings and margins. Risk: Regulatory developments, US pricing pressure, competition and acquisition integration costs could affect performance. SEBI RA Disclaimer: Umang Rajesh Bhutada is a SEBI-registered Research Analyst (INH000023001). This content is for educational and informational purposes only and is not investment advice. Securities investments are subject to market risks. Please consult a qualified financial professional before making investment decisions. Pre-results analysis. Q2 figures are not included here.